- 8.2 million Chinese adults live with non-segmental vitiligo.
- 174 patients enrolled in Phase III trial for povorcitinib, an oral JAK1 inhibitor.
- 18.9% of patients achieved ≥75% facial repigmentation in global trials.
Experts view the Phase III trial of povorcitinib as a significant step toward systemic treatment for vitiligo, though its efficacy and safety profile require further validation.
China's 8 Million Vitiligo Patients Await a Systemic Breakthrough
SHENZHEN, CHINA – November 19, 2026 — For millions of people living with vitiligo, the condition is far more than a cosmetic concern; it is a chronic autoimmune disease that visibly and often unpredictably alters one's skin, carrying a profound psychological weight. In China, where an estimated 10.3 million people live with the condition—8.2 million of whom have the non-segmental variant—the search for effective, systemic treatment has long been a story of unmet needs and managed expectations.
Today, that narrative may be inching toward a pivotal shift. Dermavon Holdings Limited, the dermatology subsidiary of China Medical System Holdings Ltd. (CMS), announced the enrollment of the first patient in a China Phase III clinical trial for povorcitinib, an innovative oral JAK1 inhibitor. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the trial will span 44 clinical research centers across the country, aiming to enroll 174 adult patients.
The development marks a critical juncture not just for the patients awaiting a systemic option, but for Dermavon itself, as the company maneuvers toward a highly anticipated independent listing on the Hong Kong Stock Exchange.
The Clinical Gap: Moving Beyond Creams and Light
To understand the significance of an oral treatment for vitiligo, one must first understand the current landscape of care. For decades, the standard of care in China has relied heavily on layered, localized approaches. Patients typically begin with topical corticosteroids or calcineurin inhibitors for limited patches. As the disease spreads, the burden of treatment shifts to hospital-based narrowband ultraviolet B (NB-UVB) phototherapy or targeted 308nm excimer lasers.
While these treatments can be effective for localized lesions, they are labor-intensive, require frequent clinical visits, and often fall short for patients with widespread, rapidly progressing depigmentation. Earlier this year, Dermavon successfully commercialized ruxolitinib phosphate cream (Lumirix), marking the first targeted topical drug approved in China for vitiligo. Yet, for patients whose condition covers large percentages of their body surface area, applying a cream twice daily is practically and financially unfeasible.
"There has always been a ceiling to what we can achieve with topicals and light therapy alone, particularly for extensive disease," noted one Beijing-based dermatologist familiar with the trial. "An oral targeted therapy addresses the systemic autoimmune drivers of the disease, rather than just treating the symptoms at the surface."
Povorcitinib works by suppressing the overactivity of proinflammatory cytokines signaling through the JAK-STAT pathway, which are believed to drive the destruction of melanocytes. Recognizing the urgent need for such systemic interventions, China's Center for Drug Evaluation (CDE) previously granted povorcitinib Breakthrough Therapy designation, a regulatory fast-track reserved for drugs showing substantial improvement over existing therapies for serious conditions.
Weighing the Promise Against the Profile
As with any medical breakthrough, the promise of povorcitinib must be weighed against the rigorous realities of clinical data. Dermavon in-licensed the compound from U.S.-based Incyte in March 2024, securing exclusive rights in Mainland China, Hong Kong, Macao, Taiwan, and 11 Southeast Asian nations.
Incyte’s global Phase III trials—STOP-V1 and STOP-V2—offer a preview of what Chinese patients and regulators might expect. In those ex-China studies, the drug met its primary endpoints, demonstrating statistically significant improvements in facial repigmentation at Week 52. However, a closer look at the data reveals the stubborn nature of vitiligo: 18.9% of povorcitinib-treated patients achieved a 75% or greater improvement in their facial Vitiligo Area Scoring Index (F-VASI75), compared to single-digit percentages in the placebo groups.
While statistically triumphant, the clinical reality is that fewer than one in five patients achieved this threshold of substantial facial repigmentation, and total body responses were even more modest.
Furthermore, the introduction of any systemic Janus kinase (JAK) inhibitor invites necessary scrutiny regarding safety. While povorcitinib was generally well-tolerated in global trials—with common side effects limited to nasopharyngitis, acne, and upper respiratory infections—the broader JAK inhibitor class carries well-documented black-box warnings in several global markets. These warnings detail risks of serious infections, major adverse cardiovascular events (MACE), thrombosis, and malignancies, particularly in older populations or those with underlying risk factors.
For a non-life-threatening condition like vitiligo, the calculus of risk versus reward becomes deeply personal. Patients desperate to halt the progression of their depigmentation must navigate these potential systemic risks, a conversation that will require nuanced guidance from China's dermatological community.
The Corporate Mechanics of Skin Health
Beyond the clinical implications, the povorcitinib trial is a masterstroke of corporate timing. CMS has been meticulously carving out Dermavon as a standalone powerhouse in the skin health sector. With a portfolio spanning vitiligo, atopic dermatitis, and psoriasis, Dermavon is currently applying for a separate listing on the Main Board of the HKEX by way of introduction.
The financial stakes are considerable. Dermavon filed for its Hong Kong listing with 2024 revenues reaching RMB 618 million, driven largely by niche therapies and the recent commercialization of ruxolitinib. By advancing povorcitinib into Phase III, Dermavon is signaling to institutional investors that it is not merely a distributor of topical creams, but a comprehensive dermatology company capable of managing a pipeline that spans from precise topical interventions to advanced systemic treatments.
"Securing a Phase III milestone for an in-licensed asset right before an IPO is a classic, highly effective strategy to boost valuation," an independent biotech analyst observed. "It proves the company can execute on clinical development in China while simultaneously building a commercial moat around a specific disease state like vitiligo."
If successful, Dermavon will effectively corner the vitiligo market in China, offering patients a continuum of care—Lumirix for localized facial lesions and povorcitinib for extensive, systemic disease.
A Shifting Paradigm for Patients
Dermavon is not alone in recognizing the vast, untapped market for systemic vitiligo treatments in China. The competitive landscape is rapidly intensifying. Global pharmaceutical giants are advancing their own oral JAK inhibitors, with AbbVie’s Rinvoq (upadacitinib) and Pfizer’s Litfulo (ritlecitinib) both showing positive Phase III data globally and marching toward regulatory submissions.
This influx of innovation is forcing a rapid evolution in how Chinese medicine approaches the disease. The recent publication of the "2025 Clinical Phototherapy Guidelines for Vitiligo," authored by over 50 leading dermatologists, underscores a medical community actively adapting to integrate advanced therapies with traditional light-based standards of care.
For the 8.2 million Chinese adults living with non-segmental vitiligo, this corporate and clinical arms race translates directly into hope. For years, these patients have navigated a healthcare system that offered them limited tools to manage a highly visible, stigmatized condition. The initiation of the povorcitinib Phase III trial does not promise an immediate cure, nor does it erase the complex safety profiles inherent to systemic immunosuppression.
What it does offer is the validation of their medical need. It represents a tangible step toward closing the gap between the limitations of current dermatological care and the comprehensive, systemic treatments that patients have long deserved. As the 174 patients enroll in clinical centers from Beijing to Shenzhen over the coming months, they are not just testing a new chemical entity; they are actively participating in the rewriting of the vitiligo treatment paradigm in China.
Topics & Related
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →